

RSV vaccine


Beyfortus

You follow the best medicine. **We'll handle the rest.**



In this year's autumn and winter virus season, we find ourselves in a unique situation with vaccines now accessible for the three primary respiratory viruses: COVID-19, RSV, and influenza. Notably, Beyfortus (RSV) has received recent approval, leading to certain ambiguities concerning its coverage under private insurance.

The CDC is now endorsing a novel immunization strategy that involves the use of nirsevimab, commercially known as Beyfortus[™]. This long-acting monoclonal antibody product will be administered beginning this autumn, aimed at safeguarding all infants under 8 months of age, as well as certain older babies who face an elevated risk of severe illness stemming from respiratory syncytial virus (RSV).



Indications, presentations and orders



Recommendations

Infants and young children

- 1 dose of nirsevimab for all infants younger than 8 months born during or entering their first RSV season.
- 1 dose of nirsevimab for infants and children 8–19 months old who are at increased risk for severe RSV disease and entering their second RSV season.

Pregnant women

 To maximize protection for babies after birth, CDC recommends seasonal administration of one dose of RSV vaccine for pregnant people during weeks 32 through 36 of pregnancy

Adults 60 years old and over

 Adults 60 years of age and older may receive a single dose of RSV vaccine using shared clinical decision-making.



Orders

Presentations:

- 5 doses, 0.5 mL, prefilled syringes.
- 5 doses, 1 mL, prefilled syringes.

Minimum to order

The minimum quantity to order is 5 vaccines.

Smartly order

• In order to avoid the possibility of over-ordering vaccines, Canid and the practice will decide the doses required for two weeks by practice, based on the patients that are eligible to receive the vaccine, with appointments for that period of time. Please note that if there are too many issues with insurance reimbursement, we may adjust ordering practices over time until we better understand reimbursements.



Purchasing RSV

- To allow us to purchase RSV for you, you must join our buying group Atlantic Health Partners (AHP).
- This change will not affect your billing.
- To join AHP, you must sign the attached document, page 4, under "member."
- Once signed, we will submit the form to AHP and receive approval to purchase RSV within 5-10 business days.



Billing strategy



Insurance coverage

A vaccine (immunization) that does not fall under one of the exclusions in the Certificate of Coverage is considered covered by insurances, after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendations for routine use published in the Morbidity & Mortality Weekly Report (MMWR) of the Centers for Disease Control and Prevention (CDC); and (3) listed on the applicable immunization schedule of ACIP.

The <u>CDC recommendations</u> mean the vaccines should be covered, without a copay, for people with private insurance.

Some insurance stated that they are supporting RSV Immunization, as Aetna, UHC and BCBS

Remember: Canid is taking the insurance risk. You just give vaccines!



Codes season 2023

Admin CPT Codes

Report the administration of palivizumab and nirsevimab with code 96372 (injection of a drug or substance, subcutaneous or intramuscular). Do not report immunization administration codes 90460-90461 or 90471-90472, as these codes are limited to the administration of vaccine and toxoid products.

Inventory CPT codes

- Respiratory syncytial virus (RSV) monoclonal antibody, (nirsevimab-alip), 0.5 mL, NDC 49281-575-15, CPT code 90380.
- Respiratory syncytial virus (RSV) monoclonal antibody, (nirsevimab-alip), 1 mL, NDC 49281-574-15, CPT code 90381.



Billing strategy

The meticulous tracking of our vaccines remains of utmost importance at this juncture. If we observe any instances where the CPT code for Beyfortus vaccine is denied, it is imperative that we promptly contact the insurance company to ascertain the underlying cause and initiate the corresponding appeal process without delay.

Based on our experience, it is plausible that certain private insurance providers may initially decline payment for the CPT code linked to the RSV vaccine inventory. Therefore, our team is prepared with the criteria for appeals in such cases.

Please note that while it is likely that denials will come in upfront, our team will proactively track them and loop you in if there's anything we need. Because Canid is taking the risk here, we will ensure that we take reduce all errors ASAP, and will bring you in if we need help to accomplish this.

